Introduction
Nitric oxide (NO) was recognised in the 1980s as a molecule involved in several physiological functions. First, NO was identified as the endothelium-derived relaxing factor (EDRF) that plays a major role in the control of the vascular tone. NO is an effector molecule responsible for the cyostatic effect of activated macrophages on tumoral cells. In addition, NO acts as a neuromediator implicated in long-term potentiation and displays retrograde messenger activity. NO results from the conversion of free L-arginine through oxidation of its guanidino group by a family of enzymes, the NO synthases. Three enzymes have been identified that are encoded by genes located on separate chromosomes and differing in their properties. Two of these enzymes are constitutive and spontaneously expressed by various cell types. They have been designated, respectively, type 1 or neuronal NOS (nNOS) and type 3 or endothelial NOS (eNOS) according to the tissue where they were first described. These two enzymes are activated by transient increases in the concentration of free calcium [Ca 2ϩ ] i , in response to specific activators of these cells (neuromediators, bradykinine, etc). They release brief 'puffs' of NO, that is produced at low concentration and plays a physiological role in cellular signalling. Recently, phosphorylation by Akt/PKB (protein kinase B) was identified as an alternate pathway of eNOS activation. A third enzyme, the type 2 or inducible NOS (iNOS) is transcriptionally regulated. iNOS is normally not expressed in resting cells in physiological situations but can be induced following their activation, mainly by cytokines, but also by other stimuli, such as hypoxia, 1 the promoter of the iNOS gene containing a responsive element to the hypoxia-inducing factor-1 (HIF-1). Both cytokine release and hypoxia occur during the course of an inflammatory response and may act in synergy for the induction of iNOS. One major role of iNOS is to participate in the nonspecific defence of the host against invading pathogens and to contribute to innate immunity. After induction, iNOS associates closely with calmodulin, explaining why its catalytic activity is rather independent of the variations of the [Ca 2ϩ ] i . The activity of iNOS is mainly dependent on the rate of synthesis of the enzyme, yet other parameters are important, such as the availability of the co-factors (flavins, NADPH, calmodulin) and that of tetrahydrobiopterin which plays a critical role in the control of NOS dimerization.
NO is a pleiotropic mediator and signalling molecule involved in a growing number of cell functions. NO is often described as a double-edged sword, inasmuch as it can exert opposite effects depending on its concentration and the cell type. This is also true for its role in apoptosis. Apoptosis, or programmed cell death (PCD), is a process by which cells activate, in response to external stimuli, a programme leading within a few hours to typical morphological alterations (membrane bebbling, chromatin condensation, cell shrinking, nucleus fragmentation). Ultimately, it results in cell death with formation of apoptotic bodies that are cleared from the organism by professional phagocytes. 2 Apoptosis differs from necrosis, uncontrolled and rapid cell death, because membrane integrity is preserved until the removal of the cells by phagocytosis, avoiding the need to release the intracellular content and to elicit inflammatory reactions.
Numerous works have analyzed the consequences on apoptosis of cell exposure to NO and have reported conflicting results. In some situations, NO activated the transduction pathways causing the cells to undergo apoptosis, whereas in other cases NO was found to protect cells against spontaneous or induced apoptosis. A number of these studies have been conducted with NO endogenously released by NOS, following their activation or the transfection of their genes, but many of these works have been performed with chemical NO donors. Some of these reagents, for instance S-nitroso-thiols, have a biological relevance since they represent a stockage form of NO. Other NO donors, of putative therapeutic interest, have contributed to unraveling the cellular pathways altered by NO; however, the involvement of these mechanisms in physiopathological situations resulting from an endogenous NO production must be interpreted with caution.
NO exhibits contradictory effects in the regulation of apoptosis since both pro-and anti-apoptotic effects have been demonstrated, stressing again the dual role, 'friend or foe', of NO. [3] [4] [5] [6] At first glance, pro-apoptotic effects seem to be associated with pathophysiological conditions and with high output NO production by iNOS, whereas the continuous release of low output NO via constitutive NOS would lead to protection. The present review will try to summarize the effects of NO on human leukemic cell apoptosis.
Modulatory effects of NO on differentiation, proliferation and cytostasis
The first evidence of a modulatory action of NO on apoptosis came from observations of several groups relating a pro-apoptotic effect of NO on murine macrophages 7, 8 and transformed fibroblasts. 9 However, it was already known that NO interfered with the differentiation, proliferation and cytostasis of various cell types, notably leukemia.
NO donors elicited the differentiation of the human monocytic HL60 leukemic cells, characterized by the induction of CD14 and non-specific esterase and the capacity to release reactive oxygen species, or ROS. 10 NO also decreased the growth and viability of most freshly isolated acute non-lymphocytic leukemia cells in vitro and induced their differentiation toward a monocytic phenotype. 11 This differentiating effect of NO donors was also observed on CD34 ϩ human bone marrow cells, with contrasting effects on erythroid and myeloid colony growth. 12 Esterase-sensitive NO donors of the diazeniumdiolate family were found to display in vitro antileukemic activity on HL60 and U937, confirming the anti-proliferative effect of NO on these cells. 13 The ligation of CD23 on acute myelogenous leukemia (AML) cells or the promonocytic U937 cell line inhibited the proliferation of the leukemic cells and induced their terminal differentiation. The engagement of CD23 induced a rapid accumulation of cGMP, followed by the activation of NF-B, a reinduction of c-fos/c-jun and promotion of the expression of the cell maturation-associated proto-oncogenes junB and cfms, whereas c-myb expression decreased. These events were prevented by NOS inhibitors, indicating that CD23-driven endogenous NO production played a role in the differentiation of these leukemic myelomonocytic cells. 14 A role for endogenous NO was also demonstrated in the antitumoral activity of all-trans retinoic acid (RA) and vitamin D3 (VD) in the U937 (and THP1) monocytic cell line. These agents triggered the expression of iNOS in these cells and their differentiation, as evidenced by the induction of CD14 and CD68 and the capacity of these cells to undergo a luminoldependent chemiluminescence in response to opsonized zymosan. Both events were blocked in the presence of NOS inhibitors, strengthening the role of NO in the VD-and RA/VD-induced growth arrest and terminal differentiation of promonocytic leukemia cells. 15 Vitamin D3 may also influence endogenous NO production and differentiation of these cells by directly increasing TNF-␣. 16 The NO-releasing agents, mesoionic 3-aryl-substituted oxatriazole-5-imine derivatives GEA 3162 and GEA 3175, and a reference NO donor SIN-1 were found to inhibit DNA and RNA synthesis in proliferating human hematopoietic cells and in the MOLT-3 leukemic T cells. These compounds also inhibited the growth of human bone marrow stem cells, CFU-GM colonies being more susceptible to the cytostatic action of NO than BFU-E. Therefore, NO-releasing drugs display cytostatic action against human malignant and non-malignant hematopoietic cells. 17 These results indicated that exposure of leukemic cells to NO, either of chemical origin or resulting from endogenous production as a consequence of NOS induction in the tumoral cells, could block their multiplication (cytostasis) and induce their differentiation.
Pro-apoptotic effects of NO
In addition to their effects on the differentiation and proliferation of various hematopoietic cells, chemical NO donors were found to stimulate apoptosis in different human neoplastic lymphoid cell lines through activation of caspases, via or independently of CD95/CD95L interaction.
NO donors triggered apoptosis in tumoral myelomonocytic cells that was potentiated with TPA treatment. 18 Inhibitors of poly(ADPribose) polymerase, or PARP, blocked NO-induced apoptosis, but not differentiation of these cells suggesting that different pathways are modulated by NO exposure. 19 Permeant analogues of cAMP, as well as agents raising the level of intracytoplasmic cAMP inhibited NO and TPA-induced apoptosis. 20 The apoptotic effect of NO donors on HL60 and U937 cells depended on the schedule and concentration, inasmuch as the compound with the longest t(1/2) of NO delivery was the most potent inhibitor of leukemia cell and colony growth; furthermore, the NO-induced growth inhibition was associated with apoptosis in a rate and concentration-dependent fashion. 21 NO donors also significantly accentuated the apoptosis induced by the isoprenoid geranylgeranylacetone in HL60 cells. 22 Treatment of HL60 with NOC 18, a slow-releasing NO donor at physiological conditions, slightly reduced the level of Bcl-2 and activated caspase 3, but not caspase 1, through a process involving tyrosine phosphorylation. 23 A variant cell line of HL60 resistant to NO-induced apoptosis displayed increased Cu/Zn superoxide dismutase (CuZnSOD) and catalase activity, as compared to the parental NO-sensitive cells; moreover, addition of CuZnSOD or a catalase mimic inhibited NO-induced apoptosis in the parental sensitive HL60 cells, emphasizing the role of ROS in this process. 24 As an additional mechanism, the apoptosis stimulated by the NO donor SNP (sodium nitroprusside) in HL60 cells involved increased ceramide generation and magnesium-dependent neutral sphingomyelinase activity, via an activation of caspase 3.
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Activation of a caspase-3-like protease that cleaved PARP (polyADP-ribose polymerase) and U1snRNP (small ribonucleoprotein) was also detected during the course of apoptosis triggered by NO-releasing compounds in the human myeloid leukemia U937; this was associated with an upregulation of the cyclin-dependent kinase (cdk) inhibitor p21 WAF1/Cip1 and later on a down-regulation of Bcl-2. 26 NO promoted cell death in murine (Raw 264.7) and human monocytic/macrophages (U937), both by p53-dependent (Raw 264.7) and p-53-independent (U937) executive death pathway. Transfection of RAW with bcl-2 suppressed NO-1687 induced apoptosis but only delayed PARP degradation, indicating that PARP cleavage is dispensable for the apoptotic process. 27, 28 Peroxynitrite which results from the reaction of NO with superoxide O 2 · Ϫ was found to cause apoptosis in HL60 and U937 leukemic cell lines, but not in normal endothelial cells and peripheral blood mononuclear cells, through an indirect activation of caspase 3. 29, 30 The induction of apoptosis in U937 cells by a NO donor simultaneously induced the production of various chemokines, suggesting in vivo the possibility of a recruitment of phagocytes to eliminate the dying cells. 31 In Jurkat leukemic T cells, NO induced apoptosis in cells sensitive to CD95-mediated kill, far less in a CD95-resistant sub-clone. NO stimulated mRNA expression of CD95 and APO-2/TRAIL ligands in these cells. Moreover, NO triggered apoptosis in freshly isolated human leukemic lymphocytes which were also sensitive to anti-CD95 treatment. The ability of NO to induce apoptosis correlated with caspase-8 activation. These results were confirmed in a model of coculture of human lymphoid target cells with activated bovine endothelial cells generating NO. These data provide evidence that NO-induced apoptosis in human neoplastic lymphoid cells strictly requires activation of caspases, in particular caspase 8 which acts downstream of CD95. However, according to the cell line, this activation was dependent or not of the CD95 receptor/ligand system. 32 More recently, the same group showed that Jurkat cells exposed to a NO donor presented alterations in various parameters such as: decrease in the concentration of cardiolipin, down-regulation in respiratory chain complex activities, release of cytochrome c into the cytosol, activation of caspase-9 and caspase-3, increase in the number of cells with low mitochondrial transmembrane potential and high level of ROS production. These changes were less pronounced in a CD95-resistant Jurkat subclone and were prevented by transfection of Jurkat cells with bcl-2. These results suggested that the mitochondrial damages induced by NO in this peculiar type of human leukemia cells were crucial for activation of caspase and apoptosis. Drug-induced apoptosis has been associated in certain cases with an induction of NO production. For instance, a significant increase in NO production was observed during paclitaxel-induced apoptosis in U937 monocytic leukemia cells. 35 Treatment of the Jurkat leukemic T cells with thapsigargin (TG), an inhibitor of Ca 2ϩ ATPase, stimulated an increase in intracytoplasmic and mitochondrial calcium concentration and induced NO generation, JNK (c-jun NH(2)-terminal kinase) activation and apoptosis. TG-induced NO production and apoptosis were prevented in the presence of a calcium chelator or of a NOS inhibitor. When Jurkat were transfected with bcl-2 or bcl-X(L), TG still elicited an early increase in calcium but the NO production, late calcium accumulation and apoptosis were markedly impaired, whereas apoptosis triggered by a chemical NO donor was unaffected. Overexpression of bcl-2 or bcl-X(L) also inhibited TG-induced decrease in mitochondrial membrane potential, release of cytochrome c, as well as the sequential caspase 3 and JNK Leukemia activation. These data indicated that Ca 2ϩ -dependent activation of NOS led to apoptosis; the latter was inhibited by bcl-2 or bcl-X(L) which prevent the increase in [Ca 2ϩ ] i required for NOS activation. Surprisingly, however, the overexpression of these molecules did not prevent the apoptosis triggered by a NO donor. 36 In summary, pro-apoptotic effects of NO were reported in various leukemic cells, mostly of myelomonocytic origin, but also in acute T cell leukemia and erythroleukemia. It should be noted that most of these studies were performed with continuous cell lines exposed to NO released by chemical donors.
Mechanism of NO cytotoxicity and pro-apoptotic action
NO is a small radical gas that diffuses rapidly from the cell where it is produced to neighboring cells. In aqueous solution, NO reacts with O 2 , leading to the formation of nitrite, its rate of diffusion is more rapid than its rate of reaction with O 2 , which is the major pathway of decay of NO in aqueous medium. An oxidative stress concomitant with an elevated NO production may result in damage to the cells. Indeed, when superoxide O 2·
Ϫ is produced as a consequence of oxidative metabolism, it is generally converted by the superoxide dismutase(s), SOD into H 2 O 2 , which is then eliminated by catalase. However, depending on their relative flow of production, superoxide can also react with NO, leading to the formation of peroxynitrite ONOO
Ϫ . Thus there is competition for O 2·
Ϫ between SOD and NO and, depending on the kinetics of reaction and concentration, this may or may not lead to peroxynitrite production. The latter is highly toxic and a potent oxidant of various macromolecules, such as lipids, nucleic acids and proteins. Peroxynitrite can also oxidise thiols and nitrate proteins on tyrosine residues and the detection of nitrotyrosine is a characteristic feature of peroxynitrite formation.
NO also reacts with molecular O 2 to produce nitrogen oxides and since both molecules are hydrophobic this reaction takes place preferentially in cell membranes. In addition, in the presence of free iron, NO can potentiate an oxidative stress. In contrast, NO may also react with molecular species produced during oxidative stress and convert them into less damaging species. Indeed, NO may react with the hydroxyl radical leading to the formation of compounds less harmful for the cells. For instance, the NO donor PAPANONOate completely protects phospholipids, including phosphatidylserine (PS), from oxidation in HL60 cells treated with a generator of oxidative stress, 2,2Ј-azobis(2,4-dimethylisovaleronitrile) (AMVN), presumably via the ability of NO to react with lipidderived peroxyl radicals and terminate the propagation of lipid peroxidation. Yet, NO did not prevent PS externalization resulting from AMVN-induced apoptosis and even potentiated the inhibition of aminophospholipid translocase. 37 
Mitochondria
NO interferes with enzymatic components of the mitochondria causing reversible inhibition of the respiration, but also irreversible inactivation of some mitochondrial enzymes containing haem or Fe-S moieties. NO displays high affinity to the iron group of haem, explaining its capacity to stimulate soluble guanylate cyclase activity. For the majority of the other haem-containing proteins, however, the binding of NO to haem leads to an inhibition, generally reversible, of the functions of these proteins. This is true for cytochrome oxidase. By competing with oxygen for cytochrome oxidase, low concentration of NO can inhibit electron transport. This may lead to an impairment of respiration and ATP synthesis and finally to a release of mitochondrial calcium in the cytoplasm. As described above, NO can react with superoxide, which is formed continually in mitochondria, leading to the formation of peroxynitrite.
NO produced through the activation of a NOS is released into the cytoplasm (iNOS and nNOS) or near the internal face of the plasma membrane (eNOS). Before diffusing to the mitochondria, a certain amount of NO can thus react with various targets, such as thiol-containing proteins, including reduced glutathione, GSH, which is present at high concentrations in most cell types. This means that only a part of the NO released can react with O 2· Ϫ produced in the mitochondria, leading to peroxynitrite formation.
NO and peroxynitrite inhibit the mitochondrial MnSOD, thus providing another way to augment the concentration of superoxide in the mitochondrial matrix and favoring an amplification loop of peroxynitrite formation and the initiation of mitochondrial damages. NO/peroxynitrite irreversibly inactivate the enzymes of the respiratory chain (complexes I, II and III) and of the citric acid cycle (aconitase) which contain Fe-S clusters. NO also inactivates GAPDH via S-nitrosylation resulting in an inhibition of glycolysis and ultimately in impairment of ATP synthesis. Such an alteration of the energetic metabolism of the cells would prevent an efficient activity of the Ca2ϩ pumps (the plasma membrane and endoplasmic reticulum calcium ATPases) leading to dramatic increases in the [Ca 2ϩ ] i . The oxidation by peroxynitrite of thiol-containing mitochondrial proteins and of NAD(P)H leads to the opening of the mitochondrial megachannel through the formation of pores and release of calcium. The swelling of the inner membrane of the mitochondria elicits the release into the cytoplasm of components of the mitochondrial matrix, including molecules involved in the control of apoptosis such as APAF-1 (apoptosis protease activating factor 1) and cytochrome c. The latter, in conjunction with dATP, activates caspase 9, which downstream stimulates caspase 3, leading to the proteolysis of ICAD (inhibitor of CAD, caspase activated DNAse). The degradation of ICAD allows the CAD endonuclease to migrate to the nucleus and to exert its enzymatic activity, ultimately resulting in the internucleosomal cleavage of DNA.
The mitochondrial permeability transition pores were shown to account for the dissipation of the mitochondrial transmembrane potential ⌬m during lymphocyte apoptosis. Pharmacological inhibitors of the permeability transition, such as bongkrekic acid or cyclosporin A prevented ⌬m disruption. 38, 39 NO was reported to directly induce the mitochondrial pore transition permeability (PTP) and disruption of the mitochondrial transmembrane potential ⌬m in intact thymocytes, leading to an increase in cytoplasmic-free calcium and causing the liberation of apoptogenic factors from mitochondria which can induce nuclear apoptosis in isolated nuclei in vitro. 40 Inhibitors of mitochondrial permeability transition prevent the mitochondrial as well as all post-mitochondrial signs of apoptosis induced by NO such as the generation of ROS, exposure of phosphatidylserine (PS) on the outer plasma membrane leaflet and nuclear apoptosis (Figure 1 ). However, it was recently shown that exposure of murine macrophages to high concentrations of NO induced a release of cytochrome c into the cytosol, that preceded a surprising increase in ⌬m. Effects of NO on mitochondria. NO inactivates mitochondrial enzymes (complexes I-V) including cytochrome c oxydase leading to a de-energization of the cells. NO also inhibits enzymes with Fe-S clusters, leading to iron release that stimulates the Fenton reaction with formation of the toxic OH radical. In addition, NO induces the dissipation of the transmembrane mitochondrial potential ⌬m and the transition of permeability. This leads to the production of ROS, the externalization of phosphatidylserine (PS) and to the release of pro-apoptotic molecules, such as the apoptosis inducing factor (AIF) that stimulates nuclear events of apoptosis.
The cytochrome c released was modified by tyrosine nitration as a result of peroxynitrite formation in the mitochondria. 41 Therefore, the resulting effect of NO on ⌬m appears to depend on several parameters such as the NO concentration, cell type and level of superoxide formation in the mitochondria.
Recently, although poorly characterized, the existence of a calcium-dependent mitochondrial NOS, or mtNOS, and its relevance for mitochondrial bioenergetics was reported. 42, 43 NO, either provided by an NO donor as well as by mtNOS stimulation by loading mitochondria with calcium, was found to cause mitochondrial matrix acidification and a drop in mitochondrial transmembrane potential. 44 The uptake of Ca(2ϩ) by mitochondria triggered mtNOS activity leading to the release of cytochrome c from isolated mitochondria in a Bcl-2-sensitive manner and to increased lipid peroxidation. Both events were prevented by NOS inhibitors, a superoxide dismutase (SOD) mimic, and a peroxynitrite scavenger. However, mtNOS-induced cytochrome c release was not mediated via the mitochondrial permeability transition pore because the release was aggravated and not inhibited by cyclosporin A. 45 The biochemical properties of this mtNOS, its distribution (ubiquitous or restricted to some cell types) and the regulation of its activity are still elusive but it may contribute to the regulation of apoptosis.
Recently, it was reported that mitochondria are endowed with a nitrite reductase-like catalytic activity. Nitrite in contact with respiring mitochondria accepts reducing equivalents from the ubiquinone cycle of the respiratory chain. Therefore, recycling of NO 2 via these electron carriers is a threat to energy-linked respiration since NO was shown to slow the energy-linked respiration down and to trigger a mitochondrial source for superoxide radicals. 46 
Ribonucleotide reductase
Exposure to NO was reported to inhibit ribonucleotide reductase, an enzyme involved in the production of deoxyribonucleotide. This leads to impairment of DNA synthesis and of cell proliferation. 47 
PARP
NO and peroxynitrite cause single strand breaks in DNA, leading to the activation of poly(ADP-ribose) polymerase or PARP. 48 PARP is a nuclear DNA-binding protein that participates in the DNA base excision repair pathway. The disruption of the PARP gene renders mice resistant to cerebral ischemia through an inhibition of iNOS, emphasizing its role in the deleterious effect of NO in this system. 49 Once activated, PARP transfers ADP-ribose groups from NAD ϩ to various nuclear proteins (including PARP itself). This leads to a consumption of NAD ϩ and the resynthesis of NAD ϩ finally results in an exhaustion of the pool of ATP and a deficit in cellular energy. Therefore, despite the fact that PARP is dispensable for apoptosis as mentioned previously, it contributes to modulating the process of cell death. Apoptosis is an energy-requiring pathway and the PARP-induced ATP depletion would block this process, which explains why PARP is one of the major substrate of the effector caspases (such as caspase 3) during apoptosis. As NO is a regulator of caspase activity (see below), this provides a mean, via PARP, of finely tuning apoptosis vs necrosis.
P53
In some cell types (murine macrophages, mesangial cells, pancreatic cells) where NO exerts a pro-apoptotic effect, exposure of cells to NO can lead to up-regulation of the tumor suppressor protein p53, through the damages caused to DNA such as single strand break. 50, 51 Expression of p53 induces either a stable growth arrest or programmed cell death. Whether the growth arrest is dependent on the transcriptional induction of the protein p21 WAF1/CIP1 , the mechanisms underlying p53-dependent apoptosis are not fully understood but appear to involve the transcriptional induction of redoxrelated genes, the formation of ROS and the oxidative degradation of mitochondrial components. 52 P53 positively transactivates p21 WAF-1 , an inhibitor of cdk, and pro-apoptotic genes such as bax. However, it should be recalled that p53-dependent apoptosis can occur independently of the transcriptional activation of p53-target genes 53 and in cells lacking bax. Conversely, p53 negatively transactivates the expression of anti-apoptotic genes such as bcl-2, and of iNOS itself, thus attenuating excessive NO production in a regulatory negative feedback loop. 54 Wild-type p53 was also shown to repress HIF-1-stimulated transcription; 55 this mechanism could be involved in the p53-dependent suppression of NO production, by inhibiting the HIF-1-dependent transcription of the iNOS gene. This negative feedback could explain, in part, why cancer cells co-expressing iNOS and wild-type p53 display a weaker tumoral growth than cells expressing a mutated form of p53. The role of NO in neo-vascularization is still controversial and depends on the type of tumor. However, in a model of carcinoma cells expressing iNOS grafted in nude mice, a selective growth advantage was observed for the tumoral cells expressing a mutated, as compared to wild-type p53 and this was associated with increased VEGF (vascular endothelial growth factor) expression and neovascularization. 56 The observed association of mutated p53 and high neo-vascularization could also result from a down-regulation of thrombospondin-1, an inhibitor of angiogenesis, due to a loss of wild-type p53 function.
In murine macrophages, NO is clearly pro-apoptotic and acts through accumulation of the tumor suppressor p53, casLeukemia pase 3 activation and internucleosomal DNA fragmentation. As nitroso-thiols are probably the major form of biologically active NO, S-nitroso glutathione (GSNO) was used to test the role of MAP (mitogen activated protein) kinases in the induction of apoptosis in these cells. GSNO triggered activation of all three MAP kinases, but whereas the blocking of ERK1/2 (extracellular regulated kinase) by the specific PD98059 inhibitor increased apoptosis, that of p38 with SB203580 left apoptosis unaltered. In contrast, antisense depletion of JNK1/2 resulted in an inhibition of p53 accumulation and induction of apoptosis at low GSNO concentrations, but not at high concentrations. 57 Activation by NO of the JNK1/2 pathway may thus lead to p53 accumulation, in addition to direct activation of p53 through NO-induced DNA damage. However, one cannot exclude that accumulation of p53 may be because it loses its function due to interaction with NO.
Proteasome
Recently, NO was shown to affect the activity of the proteasome, a multicatalytic complex of proteases in charge of the degradation of ubiquitinated proteins. Inhibition of the proteasome was shown previously to result in p53 accumulation. 58 The accumulation of p53 in murine macrophages exposed to NO, either of chemical origin or resulting from the stimulation of endogenous iNOS, was found to result from an NO-dependent inhibition of proteasome activity. Moreover, diverse NO donors inhibited in vitro the ATP-dependent degradation of polyubiquitinated p53 by the 26S proteasome. These results imply that NO-induced apoptosis and accumulation of p53 are, at least in part, mediated by inhibition of the proteasome. 59 In addition, the proteasome is involved in the degradation of the IB inhibitor, which is a prerequisite for the nuclear translocation of the NF-B complex and its activity as a transcription factor. The inhibition by NO of the proteasome would thus explain its reported inhibitory effect on NF-B activation. It should be mentioned, however, that the effect of NO on the NF-B complex is controversial, other groups having reported a stimulatory action of NO on NF-B. Yet, a possible impairment by NO of the activation of NF-B through a prevention of IB degradation by the proteasome would provide an additional means for NO to favour apoptosis, inasmuch as NF-B has been reported in numerous systems to rescue cells from the apoptotic process. In addition to its transcriptional effect through p53, NO, by inhibiting the proteasome, would also prevent the degradation of the pro-apoptotic protein bax, 60 providing an additional way to stimulate apoptosis. This would explain the pro-apoptotic effect of NO in p53-deficient cells, such as HL60. p21 is also degraded by the proteasome; 61 preventing this degradation by NO would help in maintaining a high level of p21 in the cells, thus contributing to an inhibition of cell proliferation.
These effects are summarized in Figure 2 .
Caspases
Caspases are a family of cysteine proteases involved in various steps of the apoptotic process, upstream and downstream of the mitochondrial permeability transition. Several studies have established that NO and its redox congeners such as NO ϩ can modulate the catalytic activity of these enzymes. Whether it is now clear that NO inactivates isolated caspases in vitro, a number of reports have described the possibility for NO to indirectly stimulate the process of pro-caspase activation in various cells through mechanisms that are not fully understood. 62 In the human myelomonocytic HL60 cells, two chemical NO donors, SNAP and SNP, were found to stimulate caspase 3, thus contributing to the induction of apoptosis in these cells. 23 In murine RAW 264.7 macrophages as well as in human U937 cells, the apoptosis triggered by a chemical NO donor required the activation of different caspases for the cleavage of PARP and of the U1-70kDa snRNP. 26, 28 The stimulation of caspase and induction of apoptosis by NO was impaired in variants of RAW cells with a low intracellular concentration of glutathione. Moreover, depletion of glutathione increases the resistance of RAW 264.7 cells to NO-induced apoptosis, suggesting a role for ROS in this process. 63 
Anti-apoptotic effects of NO
In contrast to the above results, an inhibition of apoptosis by NO has been demonstrated in different cell types; in addition, the presence of an iNOS or less frequently of a constitutive NOS, exerting an anti-apoptotic role has been detected in various normal and tumoral cells (reviewed in Ref. 64 ). An anti-apoptotic role for NO was first suggested for ex vivo mature B cells cultured with NO donors which resulted in delayed PCD and a rescue from antigen-induced apoptosis. The mechanism involved a cGMP-dependent process and the sustained expression of the proto-oncogene Bcl-2 indicating that a pathway linked NO signaling with Bcl-2 expression. 65 Purine antimetabolites, including aminoguanidine, a specific inhibitor of iNOS, inhibited the NO release observed in normal B cells activated by polyclonal mitogens and simultaneously triggered apoptosis in these activated cells. 66 Mannick et al 67 reported the constitutive expression, at low level, of an iNOS in Epstein-Barr virus (EBV)-transformed human B lymphocytes and Burkitt's lymphoma cell lines. The NO released contributed to maintain EBV latency through down-regulation of the expression of the immediate-early EBV transactivator Zta. NO also inhibited apoptosis in these B lymphocyte cell lines through cGMP-independent mechanisms, in contrast with the previous results.
The presence of an iNOS was demonstrated in B cells of patients with chronic B cell lymphocytic leukemia (B-CLL). The iNOS present in the tumoral B cells was functionally active and, as for monocytes, 68 ligation of CD23 expressed on B-CLL resulted in an increased iNOS expression and augmentation of the catalytic activity. The inhibition of NO production by iNOS inhibitors stimulated the apoptotic process in tumoral cells. This effect was counteracted, at least partially, by ligation of the CD23 molecule suggesting that the NO generated through CD23 engagement displayed an antiapoptotic effect. 69 The CD95/Apo-1/Fas molecule was either undetectable or expressed at low levels on tumoral cells and its ligation did not lead to significant apoptosis; yet, in the presence of an iNOS inhibitor a potentiation of the apoptotic effect was observed. Therefore, the inhibition of endogenous NO release led to apoptosis and was further increased by engagement of Fas. These studies demonstrated that B-CLL tumoral B cells spontaneously expressed iNOS and that the NO released exerted an anti-apoptotic action that contributed to the resistance of the leukemic cells to PCD.
Freshly collected B-CLL do not or very rarely display characteristic features of apoptosis, suggesting that cells undergoing PCD are rapidly cleared from the blood by phagocytes. In vitro, B-CLL leukemic B cells, but not normal B cells, are rescued from spontaneous apoptosis by contact with normal bone marrow stromal cells. This suggested that the latter cells might provide in vivo a signal that counteracted the normal process of apoptosis, thus conferring to the tumoral cells a selective advantage. 70 One can thus speculate that in vivo leukemic cells receive a signal that leads to the induction of iNOS and contributes, via the NO released, to protect these cells from the normal apoptotic process. Serum of patients with B-CLL contained elevated levels of biologically active soluble CD40L that can prolong survival of the tumoral cells and mediate their resistance to FasL and fludarabine in vitro. 71 Thus, it would be worth testing the possibility that engagement of CD40 on B-CLL B cells leads to iNOS up-regulation. The constitutive expression of iNOS associated with NO-dependent protection of apoptosis in B-CLL has also been reported by Levesque et al, 72 who found in addition that iNOS expression was increased by IFN-␥ and IL-4.
The presence of iNOS was also detected in the ESKOL cell line derived from the leukemic cells of a patient with hairy cell leukemia (HCL), another chronic malignancy affecting B cells at a pre-plasma cell stage of differentiation; this cell line released TNF-␣, in agreement with the fact that iNOS and TNF-␣ cross-amplify each other. 73 Similar results were reported for ESKOL cells and for tumoral cells of HCL patients and it was shown that NO released played an anti-apoptotic role. 74, 75 iNOS expression was also detected in seven out of eight human T cell leukemia virus type-I (HTLV-I)-infected cell lines (ATL-derived lines and in vitro transformed lines). Four out of nine ATL (adult T cell leukemia) patients of different subtypes (chronic or acute) also showed iNOS expression and the latter was found in all subtypes of ATL. In NOS inhibitor (N G -monomethyl-L-arginine: L-NMMA)-containing medium, an iNOSpositive ATL cell line showed growth inhibition and DNA ladder typical of apoptosis. Although only a limited number of patients was analyzed, these results suggest that NO may be involved in the invasive character of ATL cells. 76 The expression of the iNOS gene was confirmed in HTLV-I-infected T cell lines expressing the viral transactivator Tax by Mori et al. 77 In addition, they showed that the transcriptional regulatory region of the hiNOS gene was activated by Tax in Jurkat, independently of NF-B. Furthermore, iNOS mRNA was detected in leukemic cells from ATL patients, implying that the expression of the hiNOS gene is involved in the pathogenesis of HTLV-I-associated diseases. Transfection of HTLV-I p40tax in U937 cells induced iNOS mRNA expression and NO production, that was further enhanced by IFN-␥. 78 HTLV-I p40tax can act thus as a transactivator of NO production in cells of monocyte/macrophage lineage.
These results indicate that tumoral cells from patients with various types of leukemia constitutively express an iNOS and that the NO released protects the tumoral cells from apoptosis. In some instances, the induction of the iNOS in the tumoral cells may result from the transactivation of the gene by retrovirus, but in other situations such as B-CLL, the signal is unknown.
Such protection afforded by an endogenous NOS appears not to be restricted to some particular cell types, such as leukemia but might be a more general phenomenon allowing tumoral cells to escape the normal process of cell death.
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Possible mechanisms of NO anti-apoptotic action cGMP One of the major cellular effects of NO is activation of the guanylyl cyclase, leading to increased cGMP concentration. As stated previously, a cGMP-dependent mechanism has been demonstrated in the observed protection by NO of the apoptosis in mitogen-activated B lymphocytes. 65 A contribution of cGMP to the NO anti-apoptotic effect has also been reported in other situations, such as rat motoneurons, eosinophils, ␥␦ T cells, hepatocytes. The mechanism probably involves the stimulation by cGMP of PKG (cGMP-dependent protein kinases), but the substrates of these kinases have not yet been identified (Figure 3) . In most instances, however, the protection afforded by NO is clearly cGMP-independent, as it is the case for EBV B cells. 67 
Caspases
Different laboratories have demonstrated that exposure in vitro of purified caspases to NO leads to their inactivation
Figure 3
Involvement of the cGMP pathway in NO protection toward apoptosis. Through its activation on the haem moiety of guanylyl cyclase, NO elicits the formation of cGMP from GTP. In turn, cGMP, besides its effect on ion channels, activates specific cGMPdependent kinase(s) (PKG). Alternatively, cGMP, via the action of cyclic nucleotides phosphodiesterases can lead to an increase in cAMP and to the activation of cAMP-dependent kinase (PKA). Both PKA and PKG could phosphorylate substrates involved in the control of apoptosis.
Leukemia through S-nitrosylation of the cystein in the active site and/or oxidation. [79] [80] [81] [82] [83] [84] NO inhibited caspase-3 in vivo by S-nitrosation of the Cys 163 in the catalytic site of the enzyme in models of human endothelial cells transfected with tagged caspase 3 p17 subunit. 85 Mass spectrometry analysis revealed that other cysteines in caspase 3 were also modified by Snitrosylation but that only the Cys 163 in the catalytic site was resistant to transnitrosation in the presence of glutathione. 86 An inhibition of caspase activation has also been observed in various intact cells (hepatocytes, endothelial cells, breast carcinoma cells, lymphoid cell lines) exposed to NO, either provided by chemical NO donors or generated by endogenous NOS, indicating that such an inhibition contributed to the anti-apoptotic effect of NO. 64, 84, 87 Moreover, transfection of the iNOS gene inhibited TNF-␣-induced activation of caspase 8 in hepatocytes and apoptosis in endothelial cells. 82 
NO and the Fas pathway
The impairment by NO of caspase 3 activity through S-nitrosylation explains its inhibitory effect on Fas-induced apoptosis. 88, 89 In Jurkat T cells, exogenous NO donors as well as NO generated via transfection of the iNOS gene inhibited APO-1/Fas-mediated apoptosis through an inhibition of the caspase 3 activity through S-nitrosylation. In addition, apoptosis triggered by overexpression of FADD (Fas-associated death domain protein) or caspase 8, two molecules acting downstream of Fas and upstream of caspase 3, was also inhibited by NO. 89 By conferring resistance to apoptosis, NO may thus contribute to the pathogenesis of autoimmune diseases by preventing the deletion of autoreactive T cell clones. This would also explain, in part, why B-CLL are relatively insensitive to Fas-mediated cell death and why there is a potentiation of L-NAME-induced apoptosis by co-stimulation of the Fas pathway. 69 Conversely, the engagement of Fas was recently demonstrated to stimulate the denitrosylation of caspase 3, leading to its activation. 90 The antagonistic regulation of caspase activation by NO and Fas through S-nitrosylation/denitrosylation of the cysteine in the active site would provide a fine tuning of the apoptotic process (Figure 4 ). The activity of other molecules involved in the apoptotic process, such as ras and ion channels, is also modulated by S-nitrosylation, a mechanism
Figure 4
Regulation of caspase activity by NO and Fas/CD95 ligation. NO, either produced by a NO donor or by the activation of the iNOS through cytokine stimulation can S-nitrosylate the active cysteine of caspases, leading to their inactivation. In contrast, ligation of CD95 triggers the denitrosylation of these cysteines (via an unknown mechanism), resulting in an activation of caspases.
that could thus be involved in the modulation of numerous transduction pathways.
Members of the bcl-2 family
Prevention by NO of the cleavage of the anti-apoptotic protein bcl-2 has been observed in B lymphocytes 65 and in other cell types such as breast carcinoma cells and hepatocytes. The protective action of NO on the mitochondrial steps of apoptosis may be explained, at least in part, by its inhibitory effect on caspase activation. The bcl-2 interacting protein bid is cleaved by caspase 8 following Fas stimulation and is subsequently translocated to the mitochondria where it stimulates the release of cytochrome c into the cytoplasm. 91 In turn, cytochrome c in conjunction with other components released by the mitochondria induce the activation of caspases, contributing to the formation of an amplification loop resulting in mitochondrial membrane depolarization, uncoupling of oxidative phosphorylation and disruption in ⌬m. 39, 92 As an example, the suppression by NO of TNF-␣-induced apoptosis through the inhibition of several caspases is presented in Figure 5 .
In endothelial cells (EC), the induction of iNOS by cytokines or the addition of a chemical NO donor protected these cells from apoptosis induced by exposure to UVA; this was correlated to a NO-driven increase in bcl-2 expression and concomitant inhibition of UVA-induced overexpression of Bax, two events upstream of caspase activation. 93 However, the effects of NO on the expression and cleavage of the members of the bcl-2/bax family that control the mitochondrial pore transition permeability are controversial. In other situations, NO was shown to up-regulate the pro-apoptotic bax protein, probably through the activation of p53 resulting from NOinduced DNA damages, as already mentioned.
Other mechanisms
Other potential mechanisms of protection by NO may be involved, such as NO-dependent up-regulation of the heat
Figure 5
Inhibition by NO of TNF-induced apoptosis through inactivation of caspases. The cascade of the apoptotic pathways stimulated by ligation of TNF-␣ to its p55 receptor can be inhibited by NO at various steps involving the activation of a pro-caspase into active caspase, before or after the mitochondrial events. An apoptosis rescue pathway can be provided by growth factor through the activation of Akt/PKB. shock protein 70 (HSP70). NO induced HSP70 expression in rat hepatocytes through glutathione (GSH) oxidation, which was associated with inhibition of ROS generation, lipid peroxidation and protection from induced apoptosis. 94 To what extent this mechanism could contribute to NO-induced protection is still unresolved as HSP70 is not always induced in other situations where NO is clearly protective against apoptosis.
An effect of NO on the ceramide pathway may also be involved; a chemical NO donor, SNAP, was found to prevent apoptosis induced by the exposure to exogenous ceramides of various cells, including lymphocytes. 95 
Concluding remarks
The effects of NO on the apoptotic process in various cell types, notably leukemic cells, are variable and depend on its flow rate, concentration and chemical form. The possibility of reinducing a normal apoptotic process in leukemic cells by manipulating their susceptibility to NO can thus be envisaged, either by delivering appropriate NO donors or by a selective inhibition of endogenous NO, depending on the situation.
Control of apoptosis appears to be a major function of NO and the identification of the mechanisms involved in its proand anti-apoptotic action should identify new possible targets for the treatment of leukemias and other diseases.
